Xeris Biopharma Holdings (XERS) Change in Accured Expenses (2020 - 2026)

Xeris Biopharma Holdings has reported Change in Accured Expenses for 7 years, with the latest figure at -$4.7 million in Q1 2026.

• For the quarter ending Q1 2026, Change in Accured Expenses fell 445.1% year-over-year to -$4.7 million; the trailing twelve-month figure through Mar 2026 stood at -$2.3 million (down 155.07% YoY), and the FY2025 full-year result was $3.7 million, up 2.0% from the prior year.
• Change in Accured Expenses for Q1 2026 stood at -$4.7 million, down from $2.3 million in the prior quarter.
• The five-year high for Change in Accured Expenses was $15.6 million in Q2 2023, with the low at -$13.9 million in Q1 2023.
• Historically, Change in Accured Expenses has averaged -$311823.5 across 5 years, with a median of $297000.0 in 2025.
• Annual changes were most pronounced in 2022 — Change in Accured Expenses surged 52436.84% — and 2024, when it plunged 913.33%.
• Xeris Biopharma Holdings' Change in Accured Expenses stood at -$8.9 million in 2022, then soared by 121.96% to $2.0 million in 2023, then soared by 117.88% to $4.3 million in 2024, then tumbled by 45.1% to $2.3 million in 2025, then slumped by 300.56% to -$4.7 million in 2026.
• The last three Change in Accured Expenses figures came in at -$4.7 million (Q1 2026), $2.3 million (Q4 2025), and $297000.0 (Q3 2025), per Business Quant data.